24 stories mentioning SHE:000661Updated 9d ago
Every FINWIRES story that references SHE:000661, newest first.
Changchun High-Tech Industry's (SHE:000661) attributable profit fell 94% to 155 million yuan in 2025 from 2.58 billion yuan in 2024, according to a Wednesday filing with the Shenzhen bourse.Earnings per share at the drug manufacturer decreased 94% to 0.39 yuan from 6.42 yuan in the previous year.Operating income declined 10% year over year to 12.1 billion yuan from 13.5 billion yuan.
China's drug regulator approved Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Jinsai Pharmaceutical's clinical trial for its GS3-007a dry suspension, according to a Friday filing with the Shenzhen bourse.The drug promotes growth hormone secretion, helping treat idiopathic short stature, the filing said.
China's drug regulator approved Changchun High-Tech Industry's (SHE:000661) clinical trial of its GenSci136 injection, according to a Friday filing with the Shenzhen bourse.The injection is indicated for generalized myasthenia gravis, an acquired autoimmune condition characterized by impaired neuromuscular junction transmission, the filing said.It affects muscle groups and impacts chewing, swallowing, raising arms, combing hair, and climbing stairs, among other actions.
Changchun High-Tech Industry (SHE:000661) unit Jinsai Pharmaceutical received China's regulatory approval to conduct clinical trials for vuxin qibai monoclonal antibody injection, according to a Wednesday filing with the Shenzhen bourse.The drug targets non-infectious uveitis, an eye inflammation.
Showing 21-24 of 24
